TOI The Oncology Institute, Inc.
Healthcare$4.51+0.00%OpenMarket Cap: $451.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-286.93
P/S
0.84
EV/EBITDA
-14.62
DCF Value
$-6.20
FCF Yield
-5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
14.8%
Operating Margin
-6.0%
Net Margin
-8.0%
ROE
326.8%
ROA
-25.9%
ROIC
-33.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $147.4M | 14.7% | $-6.5M | $-2.5M | $— | — |
| Q4 null | $142.0M | 16.0% | $-6.9M | $-7.5M | $— | — |
| FY null | $502.7M | 15.2% | $-36.1M | $-60.6M | $— | — |
| Q3 null | $136.6M | 13.9% | $-8.1M | $-16.5M | $— | — |
| Q2 null | $119.8M | 14.6% | $-11.2M | $-17.0M | $— | — |
| Q1 null | $104.4M | 16.5% | $-9.9M | $-19.6M | $— | — |
| Q4 null | $100.3M | 14.6% | $-11.9M | $-13.2M | $— | — |
| FY null | $393.4M | 13.7% | $-60.1M | $-64.7M | $— | — |
| Q3 null | $99.9M | 14.4% | $-13.9M | $-16.1M | $— | — |
| Q2 null | $98.6M | 13.2% | $-16.4M | $-15.5M | $— | — |
| Q1 null | $94.7M | 12.6% | $-18.0M | $-19.9M | $— | — |
| Q4 2023 | $85.8M | 16.8% | $-15.3M | $-18.8M | $-0.21 | — |